Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum

Appunni, Sandeep; Rubens, Muni; Ramamoorthy, Venkataraghavan; Anand, Vivek; Khandelwal, Madhuram; Saxena, Anshul; McGranaghan, Peter; Odia, Yazmín; Kotecha, Rupesh; Sharma, Alpana

doi:10.1016/j.cca.2020.12.011

Cited by 17 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular sections present within tumor masses were quantified by immunohistochemical staining of the endothelial cell marker CD31 (Figure 3g,i). Unexpectedly, quantification did not show any difference in vessel density between Lum +/+ and Lum −/− tumors (Figure 3k), while lumican was previously described to be angiostatic [58,65,66], as opposed to other SLRPs such as biglycan [28]. Lastly, cancer cell proliferation was assessed by immunohistochemical staining of the cell cycle marker cyclin D1 (Figure 3h,j).…”

Section: Histological and Immunohistochemical Analysis Of Ovarian Tumor Sections In Wild-type And Lumican-deficient Micementioning

confidence: 83%

“…Lumican is highly expressed within the stroma surrounding several solid tumors, such as lung ADC [ 53 ] and prostate cancer [ 54 ]. These pro-tumoral properties are mainly associated with lumican-mediated up-regulations of MMP-9, focal adhesion kinases (FAK), and mitogen-activated protein kinases (MAPK) [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…The glycoprotein form was detected in the dermis [ 21 , 23 , 24 , 25 ], and the KS form of LUM was found in corneal stroma [ 26 ]. Lumican is expressed in various tumor tissues, but both positive and negative correlations with tumor aggressiveness have been reported [ 25 , 27 , 28 ], highlighting it as either a therapeutic molecule or an anti-cancer target. In breast tumors, the expression of lumican was detected at the mRNA and protein levels, and it was concluded that lumican is the most important proteoglycan in breast tumors [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry

Nizet

Untereiner

Sockalingum

et al. 2021

Cancers

View full text Add to dashboard Cite

Ovarian cancer remains one of the most fatal cancers due to a lack of robust screening methods of detection at early stages. Extracellular matrix (ECM) mediates interactions between cancer cells and their microenvironment via specific molecules. Lumican, a small leucine-rich proteoglycan (SLRP), maintains ECM integrity and inhibits both melanoma primary tumor development, as well as metastatic spread. The aim of this study was to analyze the effect of lumican on tumor growth of murine ovarian epithelial cancer. C57BL/6 wild type mice (n = 12) and lumican-deficient mice (n = 10) were subcutaneously injected with murine ovarian epithelial carcinoma ID8 cells, and then sacrificed after 18 days. Analysis of tumor volumes demonstrated an inhibitory effect of endogenous lumican on ovarian tumor growth. The ovarian primary tumors were subjected to histological and immunohistochemical staining using anti-lumican, anti-αv integrin, anti-CD31 and anti-cyclin D1 antibodies, and then further examined by label-free infrared spectral imaging (IRSI), second harmonic generation (SHG) and Picrosirius red staining. The IR tissue images allowed for the identification of different ECM tissue regions of the skin and the ovarian tumor. Moreover, IRSI showed a good correlation with αv integrin immunostaining and collagen organization within the tumor. Our results demonstrate that lumican inhibits ovarian cancer growth mainly by altering collagen fibrilogenesis.

show abstract

Section: Histological and Immunohistochemical Analysis Of Ovarian Tumor Sections In Wild-type And Lumican-deficient Micementioning

confidence: 83%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry

Nizet

Untereiner

Sockalingum

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Lumican pro-tumorigenic effects are also observed in gastric, bladder, colon, clear cell renal, and liver cancers [ 59 , 60 , 61 , 62 ]. A high lumican expression in gastric cancer tissues indicates a poor patient prognosis [ 48 ].…”

Section: Lumican Structure Function and Expression-correlation With Carcinogenesismentioning

confidence: 99%

“…On the other hand, the lumican expression is suggested to attenuate discrete tumor progression, including pancreatic cancerand melanoma, as recently discussed [ 59 ]. Thus, lumican was shown to inhibit cancer cell proliferation inthe early stages of pancreatic ductal adenocarcinoma (PDAC) [ 58 ].…”

Section: Lumican Structure Function and Expression-correlation With Carcinogenesismentioning

confidence: 99%

Lumican in Carcinogenesis—Revisited

et al. 2021

View full text Add to dashboard Cite

Carcinogenesis is a multifactorial process with the input and interactions of environmental, genetic, and metabolic factors. During cancer development, a significant remodeling of the extracellular matrix (ECM) is evident. Proteoglycans (PGs), such as lumican, are glycosylated proteins that participate in the formation of the ECM and are established biological mediators. Notably, lumican is involved in cellular processes associated with tumorigeneses, such as EMT (epithelial-to-mesenchymal transition), cellular proliferation, migration, invasion, and adhesion. Furthermore, lumican is expressed in various cancer tissues and is reported to have a positive or negative correlation with tumor progression. This review focuses on significant advances achieved regardingthe role of lumican in the tumor biology. Here, the effects of lumican on cancer cell growth, invasion, motility, and metastasis are discussed, as well as the repercussions on autophagy and apoptosis. Finally, in light of the available data, novel roles for lumican as a cancer prognosis marker,chemoresistance regulator, and cancer therapy target are proposed.

show abstract

Proteoglycans and Glycosaminoglycans in Cancer

Peres

Campos

et al. 2023

Handbook of Cancer and Immunology

View full text Add to dashboard Cite

Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum

Cited by 17 publications

References 31 publications

Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry

Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry

Lumican in Carcinogenesis—Revisited

Proteoglycans and Glycosaminoglycans in Cancer

Contact Info

Product

Resources

About